« Back
Home /
tezacaftor-vx-661

tezacaftor-vx-661

Manufacturer	InvivoChem LLC
Category	Reagents & Chemicals Molecules
Type	Biochemicals
Specific against	other
Amount	5mg
Item no.	V1691-5mg
CASRN	1152311-62-0
eClass 6.1	32160405
eClass 9.0	32160490
Available
Description	InvivoChem Cat #:V1691CAS #:1152311-62-0Purity >=98% Description: Tezacaftor (formerly VX-661; trade name: Symdeko) is a second F508del CFTR corrector that is able to help CFTR protein reach the cell surface. VX-661 is potentially useful for treatment of cystic fibrosis disease. In Feb 2018, Tezacaftor was approved by FDA to treat cystic fibrosis in patients age 12 years and older. Cystic fibrosis (CF) is a genetic disease caused by defects in the CF transmembrane regulator (CFTR) gene, which encodes an epithelial chloride channel. The most common mutation, delta508CFTR, produces a protein that is misfolded and does not reach the cell membrane. VX-661 can correct trafficking of delta508CFTR and partially restore chloride channel activity. References: Sci Transl Med. 2014 Jul 23; 6(246):246ra97.
Molecular Weight (MW)	520.5
Formula	C26H27F3N2O6
CAS No.	1152311-62-0
Storage	-20C for 3 years in powder form
	-80C for 2 years in solvent
Solubility (In vitro)	DMSO: 100 mg/mL (192.1 mM)
	Water: < 1 mg/mL
	Ethanol: < 1 mg/mL
SMILES	O=C(C1(C2=CC=C(OC(F)(F)O3)C3=C2)CC1)NC4=CC5=C(N(C[CH](O)CO)C(C(C)(C)CO)=C5)C=C4F
Synonyms	VX-661; VX661; VX 661; Trikafta.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 5mg

available

Delivery expected until 6/6/2024